EUDA Health Advances Cancer Research with New Government Approval in Shenzhen

EUDA Health Advances Cancer Research with New Government Approval in Shenzhen

2026-04-28 companies

Singapore, Tuesday, 28 April 2026.
EUDA Health secured a government-backed cancer research project in Shenzhen on April 28, 2026, marking a critical biotechnology expansion as the company faces a looming Nasdaq compliance deadline.

Strategic Advancement in Cellular Therapy

On April 28, 2026, Singapore-based healthcare technology company EUDA Health Holdings Limited announced that Shenzhen Inno Immune Co., Ltd. received official approval under the 2025 Shenzhen Key Industry R&D Program [1][5]. This government-led initiative focuses on the “Key Technology Development of TCR-T Therapy for Solid Tumors” [1]. Under the supervision of the Shenzhen Science and Technology Innovation Bureau, the project is slated for implementation between January 1, 2026, and December 31, 2028 [1]. To support these research endeavors, the bureau may provide up to approximately $434,688 in funding [1].

Addressing a Rapidly Aging Demographic

This research initiative aligns directly with EUDA Health’s broader strategic focus on longevity and preventive healthcare for an aging demographic [4]. The company currently operates across Singapore, Malaysia, and China, targeting a regional population of over 1.8 billion people, of which more than 30% are aging rapidly [1][4]. To commercialize these innovations, EUDA holds non-exclusive distribution rights to market and sell selected immunotherapies from Shenzhen Inno to patients in Malaysia through its subsidiary, CK Health Plus Sdn Bhd, though the actual treatments will be administered in China [1]. EUDA’s Chief Executive Officer, Alfred Lim, noted that the project’s approval “reflects ongoing progress in advanced cellular therapy research,” adding that developments in TCR-T therapy will “continue to expand the scope of future treatment possibilities” [1].

While EUDA is expanding its clinical footprint, the company is simultaneously managing significant capital market challenges [GPT]. On April 23, 2026, the Nasdaq Listing Qualifications Department issued a written notice to EUDA Health Holdings, indicating that the company had failed to maintain the Minimum Market Value of Listed Securities (MVLS) of $35,000,000 over 32 consecutive business days, thereby breaching Nasdaq Listing Rule 5550(b)(2) [2][3][4]. EUDA has been granted a 180-calendar-day compliance period, ending on October 20, 2026, to rectify this shortfall [2][3][6]. To regain compliance and avoid a potential delisting process, the company’s market value must close at or above $35,000,000 for at least ten consecutive business days during this window [3][4].

Financial Outlook and Upcoming Milestones

Investors are now looking toward EUDA’s upcoming earnings report, scheduled to be released before the market opens on May 5, 2026 [5]. Analysts currently hold a consensus earnings per share (EPS) estimate of -$1.20, alongside expected revenues of $3.90 million [5]. As the October 20, 2026 compliance deadline approaches [3], EUDA’s ability to maintain investor confidence will likely depend on a delicate balance: advancing its newly funded cellular therapy research in Shenzhen while demonstrating sufficient financial stability to secure its continued listing on the Nasdaq Capital Market [alert! ‘Forward-looking analysis based on compliance deadlines and upcoming earnings’] [6].

Sources


Biotechnology Healthcare